NIFTY 50 23024.65 ▼ (1.37%)
NIFTY NEXT 50 63406.15 ▼ (2.61%)
NIFTY 100 23664.75 ▼ (1.6%)
NIFTY MIDCAP 100 53834.95 ▼ (2.31%)
NIFTY SMALLCAP 100 17456.5 ▼ (2.28%)
NIFTY SMALLCAP 250 16484.1 ▼ (2.12%)
NIFTY MIDCAP SELECT 12013.35 ▼ (2.78%)
NIFTY TOTAL MARKET 12091.55 ▼ (1.73%)
NIFTY BANK 48570.9 ▼ (1.58%)
SENSEX 75838.36 ▼ (1.6%)
BSE BANKEX 55020.92 ▼ (1.81%)

AstraZeneca Pharma India : Q4 2024 Financial Quarterly Report : YoY Sales Up 34.6 %, QoQ Up 25.31 %

May 28, 2024May 28, 2024| adminadmin| 0 Comments| 4:45 pm
Image is loading
Categories:

Share the post "AstraZeneca Pharma India : Q4 2024 Financial Quarterly Report : YoY Sales Up 34.6 %, QoQ Up 25.31 %"

  • Facebook
  • LinkedIn
  • X
  • Tumblr
  • WhatsApp
  • TelegramTelegram
  • Email

Highlights

  • Sales over the Year and quarter: The company experienced a substantial growth of 34.6 % in the past year, substantial increase in net sales/revenue by 25.31 %.
  • Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 8.38 %. Marginal decrease of -10.25% in other income during this quarter.
  • Profit over the Year and quarter: Significant improvement in profitability for AstraZeneca Pharma India Ltd.. Notable increase of 128.57 % in net profit Year to Year, AstraZeneca Pharma India Ltd.’s profitability increased by 149.84 % in this quarter.
  • EPS over the Year and quarter: EPS increased by 128.51 % Year to Year. EPS increased by 149.84 % in previous quarter. Positive impact on shareholders.

The comprehensive analytics outlining the performance and outlook of AstraZeneca Pharma India Ltd.”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 284.704 Cr Rs. 305.789 Cr Rs. 383.199 Cr + 25.31 % + 34.6 %
Expenses Rs. 224.85 Cr Rs. 290.74 Cr Rs. 333.68 Cr + 14.77 % + 48.4 %
Operating Profit Rs. 59.85 Cr Rs. 15.05 Cr Rs. 49.52 Cr + 229.04 % -17.26 %
OPM % 21.02 % 4.92 % 12.92 % + 8 % -8.1 %
Other Income Rs. 8 Cr Rs. 9.66 Cr Rs. 8.67 Cr -10.25 % + 8.38 %
Interest Rs. 0.09 Cr Rs. 0.61 Cr Rs. 0.07 Cr -88.52 % -22.22 %
Depreciation Rs. 4.25 Cr Rs. 3.71 Cr Rs. 3.76 Cr + 1.35 % -11.53 %
Profit before tax Rs. 63.51 Cr Rs. 20.39 Cr Rs. 54.36 Cr + 166.6 % -14.41 %
Tax % 25.81 % 22.54 % 27.37 % + 4.83 % + 1.56 %
Net Profit Rs. 17.27 Cr Rs. 15.8 Cr Rs. 39.48 Cr + 149.87 % + 128.6 %
EPS in Rs Rs. 6.91 Rs. 6.32 Rs. 15.79 + 149.84 % + 128.51 %


Today, we’re looking at AstraZeneca Pharma India Ltd.’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 34.6 %. However, it did see a marginal increase of 25.31 % from the previous quarter. Expenses ticked up slightly by 14.77 % quarter-on-quarter, aligning with the annual rise of 48.4 %. Operating profit, while down -17.26 % compared to last year, faced a quarter-on-quarter increase of 229.04 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -8.1 %, but an expansion of 8 % sequentially. Other income fell by -10.25 % compared to the last quarter, despite an annual growth of 8.38 %. Interest expenses dropped significantly by -88.52 % from the previous quarter, yet the year-over-year decrease remains at a moderate -22.22 %. Depreciation costs climbed by 1.35 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -11.53 %. Profit before tax declined annually by -14.41 % but saw an increase from the preceding quarter by 166.6 %.
Tax expenses as a percentage of profits increased slightly by 1.56 % compared to last year, with a more notable quarter-on-quarter increase of 4.83 %. Net profit rose by 128.6 % year-on-year but experienced a 149.87 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 128.51 % but a quarterly rise of 149.84 %. In summary, AstraZeneca Pharma India Ltd.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 284.704 Cr Rs. 305.789 Cr Rs. 383.199 Cr + 25.31 % + 34.6 %
Expenses Rs. 224.85 Cr Rs. 290.74 Cr Rs. 333.68 Cr + 14.77 % + 48.4 %
Operating Profit Rs. 59.85 Cr Rs. 15.05 Cr Rs. 49.52 Cr + 229.04 % -17.26 %
Net Profit Rs. 17.27 Cr Rs. 15.8 Cr Rs. 39.48 Cr + 149.87 % + 128.6 %
EPS in Rs Rs. 6.91 Rs. 6.32 Rs. 15.79 + 149.84 % + 128.51 %


In reviewing AstraZeneca Pharma India Ltd.’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 34.6 % year-on-year growth, however, there was a minor increase of 25.31 % from the previous quarter. Expenses rose by 48.4 % compared to the previous year, with a 14.77 % increase quarter-on-quarter. Operating Profit dropped by -17.26 % annually, and saw a 229.04 % increase from the last quarter.
Net Profit showed yearly increase of 128.6 %, and experienced a 149.87 % increase from the previous quarter. Earnings Per Share (EPS) rose by 128.51 % annually, however rose by 149.84 % compared to the last quarter. In essence, while AstraZeneca Pharma India Ltd. exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.

[my_shortcode1 values=”AstraZeneca Pharma India “]

Related Post